Sebastian Guth sharpens his focus at Bayer; As CD47 struggles persist, I-Mab appoints CEO
→ Bayer is refining Sebastian Guth’s role on June 30, naming him senior Bayer representative and president of Bayer US. Guth had led pharmaceuticals operations in the Americas since December 2018, and he’ll still be in charge of the pharmaceuticals business for the US and Canada, as EMEA commercial operations leader Heike Prinz handles the Latin America pharmaceuticals business. Guth is a 17-year veteran with Bayer who has also been president and CEO of the German multinational’s healthcare group in Japan. The moves come as former Roche Pharmaceuticals chief Bill Anderson is about to complete his first month as CEO. In Werner Baumann’s final days, Bayer trimmed its pipeline and also struck a radiotherapy deal with Bicycle Therapeutics worth $45 million upfront.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.